Buruli Ulcer

Buruli ulcer is a long-lasting skin infection caused by a bacterium called Mycobacterium ulcerans. The germ makes a toxin (mycolactone) that quietly destroys skin, fat, and sometimes bone. Because the toxin numbs pain, the first lump or sore is often painless and grows slowly for weeks to months. Without care, the skin breaks down and forms a deep ulcer with “undermined” edges that spread under the skin surface. Buruli ulcer mainly affects people in tropical and subtropical areas, especially near slow-moving water. It can affect any age, but many patients are children or older adults. Early diagnosis and treatment lower the risk of scarring and disability. World Health Organization+2PMC+2

Buruli ulcer is a long-lasting skin and soft-tissue infection caused by the bacterium Mycobacterium ulcerans. It often starts as a painless lump, swelling, or plaque that slowly breaks down skin and tissue to form ulcers. Without treatment, the wound can enlarge and damage deeper layers, leading to scarring and disability. Early diagnosis and antibiotics greatly improve healing and reduce the need for surgery. World Health Organization+1

Scientists know where the germ likes to live (environments around wetlands, marshes, and still streams), but the exact way it reaches people is still not fully proven. Different places may have different routes. Small skin injuries, contact with contaminated water or mud, and possibly insect or mosquito bites may play a role. PLOS+2PubMed+2

Other names

Buruli ulcer is also called Bairnsdale ulcer, Daintree ulcer, or Mossman ulcer, especially in Australia. These names come from areas where outbreaks were noticed. You may also see “Mycobacterium ulcerans disease.” CDC

Types

Doctors describe two overlapping “type” systems: clinical forms (what the skin looks like) and severity categories (how big/complex the lesion is).

Clinical forms include:

• Pre-ulcer forms: a painless papule (small bump), nodule (deeper lump), plaque (flat, thick area), or diffuse edema (swollen area). These can progress if untreated. PMC+1

• Ulcerative form: a deep skin ulcer with undermined edges and a clean base that expands slowly. Health Victoria

• Bone involvement (osteomyelitis): in severe or late cases, infection extends to bone, joints, or tendon sheaths. Cambridge University Press & Assessment

WHO severity categories help plan care:

• Category I: a single small lesion under 5 cm.

• Category II: a single lesion 5–15 cm, or non-ulcerative plaques and edematous forms in that size range.

• Category III: a large lesion over 15 cm, multiple lesions, critical sites (eye, genitals, major joints), or bone/joint disease. World Health Organization+1

Causes

Note: “Cause” here means how infection can happen or what raises risk. The root cause is the bacterium M. ulcerans, but many environmental and personal factors influence exposure or disease.

1. Exposure to slow-moving or stagnant water. Living, working, or playing near swamps, ponds, backwaters, or slow rivers raises risk. PLOS

2. Human-made environmental change. Dams, irrigation, and land disturbance can alter water flow and increase risk areas. PLOS

3. Contact with contaminated mud or plants. The germ can sit in biofilms, detritus, and wet soils; skin contact may introduce it. Dove Medical Press

4. Minor skin trauma. Cuts, abrasions, or insect bites can provide an entry point. WHO | Regional Office for Africa

5. Aquatic insects as potential vectors. Some studies suggest water bugs may carry the germ in certain regions. PLOS

6. Mosquito exposure (regional). In parts of Australia, mosquito bites correlate with cases; control measures target mosquitoes. The Guardian

7. Wildlife reservoirs (regional). In southeastern Australia, possums may carry and shed the bacterium in the environment. (Applies to that setting; not proven everywhere.) Wildlife Health Australia

8. Household proximity to known case clusters. Living in or traveling to outbreak areas increases risk. CDC

9. Age extremes. Children and older adults are often affected, likely due to exposure and skin/immune factors. World Health Organization

10. Delayed wound care. Uncleaned minor injuries after environmental exposure may allow infection. (Inference consistent with environmental entry.) PLOS

11. Poor access to clean water and sanitation. Many cases occur in rural areas with limited services. ResearchGate

12. Seasonality with rainfall/mosquitoes (regional). Some locales see seasonal peaks linked to vector activity or water changes. ScienceDirect

13. Activities with freshwater contact. Farming, fishing, washing, or recreation in at-risk waters can increase exposure. PLOS

14. Travel to endemic areas. Visitors can acquire infection and develop ulcers weeks to months after travel. CDC

15. Household or community proximity to wildlife vectors (regional). Possum-dense suburbs in Victoria have higher risk. The Guardian

16. Bites or scratches from infected animals (regional reports). Avoid direct handling of sick wildlife. Herald Sun

17. Lack of protective clothing. Bare limbs increase exposure to bites and minor trauma. World Health Organization

18. Immunosuppression (general infectious-disease risk). Severe lesions can occur in immunocompromised people, similar to other mycobacterial infections. (General risk noted in reviews.) Cambridge University Press & Assessment

19. Delayed care-seeking. Early lumps are painless and often ignored, allowing progression. Health Victoria

20. Community outbreaks and shifting hotspots. Changing local ecology may create new risk zones. CDC

Symptoms and signs

1. A new painless skin bump (papule) or lump (nodule). Often mistaken for an insect bite. Health Victoria

2. A firm, flat raised plaque. The skin feels thickened and may slowly expand. PMC

3. Painless, “cool” swelling (edema) in a limb. Diffuse swelling can be the only early sign. PMC

4. A slowly growing ulcer with undermined edges. The border overhangs because the toxin eats the tissue underneath. Health Victoria

5. Little or no pain. Mycolactone dulls pain, so lesions seem “quiet” despite tissue loss. PMC

6. Minimal fever or systemic illness. Most patients otherwise feel well. Cambridge University Press & Assessment

7. Occasional itch at onset. Early papules are sometimes itchy. Health Victoria

8. Clean ulcer base with necrosis at edges. Typical appearance guides suspicion. Health Victoria

9. Restricted movement if near a joint. Tight skin and scarring can limit range of motion. World Health Organization

10. Swollen lymph nodes (sometimes). Nearby nodes can react to infection. (Reported in clinical overviews.) PMC

11. Multiple lesions (in severe disease). More than one site may be affected. World Health Organization

12. Large lesions >15 cm (Category III). Big or complex ulcers signal advanced disease. CDC

13. Sinus tracts or undermined tunnels. Tissue loss can extend under the skin. (Described in surgical series.) PMC

14. Bone pain or tenderness if bone involved. Rare but serious complication (osteomyelitis). Cambridge University Press & Assessment

15. Scarring and contractures after healing. Late effects can cause disability without early care. World Health Organization

Diagnostic tests

Doctors combine the clinical look of the lesion with lab confirmation whenever possible. Below are 20 tests grouped as requested. Not every patient needs every test; availability varies by setting.

A) Physical examination

1. Full skin exam for typical lesion pattern. A painless ulcer with undermined edges, or a pre-ulcer nodule/plaque/edema, raises strong suspicion in people from or visiting risk areas. Health Victoria

2. Lesion measurement for WHO category. Measuring widest diameter (<5 cm, 5–15 cm, >15 cm) classifies Category I–III and guides referral and rehab planning. World Health Organization

3. Check for multiple sites and critical areas. Eye, genitals, and major joints indicate complexity and higher category. CDC

4. Assess nearby lymph nodes and edema. Nodes, swelling, and warmth help clinical staging and detect other causes. PMC

5. Functional exam of joints and tendons. Range-of-motion testing near lesions prevents late contracture. (WHO care guidance emphasizes function.) World Health Organization

B) “Manual bedside tests and procedures

6. Careful palpation and edge probing. Gentle probing defines undermining, depth, and tissue loss to plan dressings and debridement. (Standard wound assessment in BU care.) Taylor & Francis Online

7. Swab sampling of ulcer base. Sterile swabs from the undermined edge are used for PCR, smear, or culture. WHO | Regional Office for Africa

8. Fine-needle aspiration (FNA). For nodules/plaques or edematous forms without open ulcers, FNA provides material for PCR or smear. PLOS

9. Punch or excisional biopsy. When diagnosis is uncertain, a tissue core can be sent for histology and PCR. WHO | Regional Office for Africa

10. Simple wound photography and mapping. Serial photos and tracings document change during therapy, aiding clinical decisions in low-resource settings. (Common practice in BU programs.) Taylor & Francis Online

C) Laboratory & pathological tests

11. IS2404 PCR (polymerase chain reaction) — the preferred confirmatory test. It detects a repeated DNA sequence unique to M. ulcerans. High sensitivity; works on swabs, FNA, or tissue. World Health Organization+1

12. Microscopy (Ziehl-Neelsen smear). Acid-fast bacilli may be seen, but sensitivity is lower than PCR; supports diagnosis when positive. World Health Organization

13. Histopathology. Tissue shows fat necrosis, minimal inflammation, and clusters of acid-fast bacilli, helping confirm and rule out mimics. World Health Organization

14. Culture on Lowenstein-Jensen at 29–33 °C. Slow and difficult but proves viable bacteria; useful in reference labs and research. World Health Organization

15. Loop-mediated isothermal amplification (LAMP). A simpler, field-friendly DNA test piloted for BU; complements PCR where lab capacity is limited. PLOS

16. Specimen type choice (swab vs FNA vs biopsy). Selecting the right specimen by lesion type improves test yield (swab for ulcers, FNA for nodules). PLOS

17. Bacterial culture for differentials. When diagnosis is unclear, routine cultures help exclude other bacteria causing ulcers. (Used in clinical algorithms.) Medscape

18. Molecular targets beyond IS2404 in reference labs. Some studies use extra targets to confirm specificity in research settings. CDC

19. HIV testing when clinically indicated. Co-morbid immunosuppression can affect severity and care; assess per local guidelines. Cambridge University Press & Assessment

D) Electrodiagnostic tests (why they’re rarely used)

20. Nerve conduction studies / electromyography (EMG) are not part of routine BU diagnosis. They may be considered only if there is suspected nerve damage from scarring or to exclude other neuropathic causes of limb symptoms. They do not detect M. ulcerans and are seldom indicated. Cambridge University Press & Assessment

E) Imaging tests

Although BU is a skin disease, imaging can be useful in selected patients:

• Plain X-rays to look for bone involvement (osteomyelitis) in severe or long-standing ulcers. Cambridge University Press & Assessment

• Ultrasound to define fluid collections or abscesses needing drainage and to map edema. (Used in wound programs.) Taylor & Francis Online

• MRI for complex cases to show deep tissue or bone spread when surgery or advanced rehab is considered. Cambridge University Press & Assessment

Non-pharmacological treatments (therapies & other supports)

1. Professional wound cleansing and moist wound healing
   Description: Clean the ulcer gently (eg, saline/clean water), remove loose debris, and keep the wound slightly moist with modern dressings. Avoid harsh antiseptics unless directed by a clinician. Purpose: Lower bacterial load, protect new tissue, and speed re-epithelialization. Mechanism: Moist wound care maintains optimal temperature and pH, supports cell migration, and reduces secondary infection risk, which is vital while antibiotics kill M. ulcerans. CDU Researchers+1

2. Atraumatic debridement (when indicated)
   Description: Gentle removal of necrotic tissue by trained staff using conservative techniques; avoid aggressive cutting before antibiotics have taken effect. Purpose: Reduce dead tissue that feeds bacteria and delays healing. Mechanism: Debridement lowers bioburden and biofilm, improving oxygen delivery and granulation. It is typically timed after antibiotics begin to minimize spread. SciSpace+1

3. Compression and edema management (if limb swelling)
   Description: Elevation, intermittent compression wraps, and rest to reduce swelling around ulcers on legs. Purpose: Improve venous/lymph flow and reduce exudate. Mechanism: Lower tissue pressure enhances oxygenation and nutrient delivery, helping granulation tissue form. Africa Health Organisation

4. Splinting and positioning
   Description: Use splints/casts or careful positioning to protect joints near ulcers and maintain function. Purpose: Prevent contractures, fractures (if bone involvement), and stiffness. Mechanism: Stabilization reduces mechanical stress on healing tissue and keeps joints in safe ranges. IRIS

5. Physiotherapy and range-of-motion exercises
   Description: Guided, gentle exercises started early and progressed as healing allows. Purpose: Preserve motion and strength; prevent disability. Mechanism: Movement stimulates blood flow, prevents adhesions, and supports return to normal function. Africa Health Organisation

6. Function-focused occupational therapy
   Description: Training in safe movement, self-care, and adaptive techniques while wounds heal. Purpose: Maintain independence and reduce disability burden. Mechanism: Task-oriented practice improves motor patterns and protects healing tissues. Africa Health Organisation

7. Nutritional optimization (high-protein, adequate calories)
   Description: Ensure enough protein (about 1.25–1.5 g/kg/day if at risk of malnutrition), calories, fluids, and micronutrients. Purpose: Provide building blocks for collagen and immune function. Mechanism: Protein and energy support fibroblast activity, collagen synthesis, and immune cell function needed for wound closure. E-ACNM+1

8. Bed nets and insect exposure reduction
   Description: Sleep under insecticide-treated nets and reduce insect bites around the home. Purpose: Lower environmental risk factors linked with Buruli ulcer in some regions. Mechanism: Reduced biting/inoculation events may reduce exposure pathways associated with disease clusters. PLOS

9. Early case finding and community education
   Description: Teach communities to seek care early for painless nodules or ulcers. Purpose: Earlier antibiotics mean smaller wounds and fewer surgeries. Mechanism: Cuts diagnostic delay, limiting toxin-driven tissue destruction and disability. CDC

10. Pain management without over-reliance on drugs
    Description: Frequent repositioning, off-loading pressure, relaxation, and cold/warm packs as appropriate. Purpose: Control pain and improve sleep and mobility. Mechanism: Reduces inflammatory pain and central sensitization while avoiding drug side effects. Medscape

11. Psychosocial support and counseling
    Description: Counseling, peer groups, and family education. Purpose: Reduce stigma, anxiety, and depression; support adherence. Mechanism: Better mental health improves self-care and follow-up. Africa Health Organisation

12. Safe water and hygiene around wounds
    Description: Clean water for washing, hand hygiene for caregivers, and clean dressings. Purpose: Reduce secondary bacterial infection. Mechanism: Limits contamination that delays healing. CDU Researchers

13. Sun protection of scars and healing skin
    Description: Shade/cloth/sunscreen once re-epithelialized. Purpose: Prevent pigment changes and fragile scar injury. Mechanism: UV avoidance limits collagen breakdown and hyperpigmentation. Dove Medical Press

14. Smoking cessation (if applicable)
    Description: Support to stop tobacco. Purpose: Improve microcirculation and immune function for healing. Mechanism: Nicotine and CO impair oxygen delivery; stopping reverses some effects. ScienceDirect

15. Off-loading and pressure relief
    Description: Cushions, proper footwear, crutches, or slings to avoid pressure/shear over ulcers. Purpose: Prevent wound enlargement and aid closure. Mechanism: Reduces mechanical stress that disrupts granulation tissue. Dove Medical Press

16. Telehealth/regular follow-up scheduling
    Description: Structured check-ins to monitor adherence and complications. Purpose: Catch problems early; reinforce care plans. Mechanism: Timely escalation if healing stalls. Health Victoria

17. Scar care (massage, silicone sheets once healed)
    Description: After closure, use silicone sheeting and gentle massage. Purpose: Improve scar pliability and appearance. Mechanism: Silicone modulates hydration and collagen alignment. Dove Medical Press

18. Assistive devices for daily living
    Description: Simple aids for bathing, dressing, and mobility. Purpose: Maintain independence while protecting wounds. Mechanism: Reduces accidental trauma to healing skin. Africa Health Organisation

19. Household vector control and environment clean-up
    Description: Reduce stagnant water near homes; manage waste; use repellents. Purpose: Lower exposure risk to potential environmental sources. Mechanism: Environmental changes may reduce contact with the bacterium’s suspected reservoirs/vectors. CDC

20. BCG vaccine status check (context-specific)
    Description: Ensure routine vaccines are up to date; BCG offers limited, short-lived protection. Purpose: Support public-health strategies. Mechanism: Non-specific mycobacterial immunity may modestly reduce risk; it is not a primary prevention tool for Buruli ulcer. World Health Organization

---

Drug treatments

Important: WHO-recommended first-line therapy for Buruli ulcer is rifampicin + clarithromycin for 8 weeks; other antibiotics below have been studied or used in specific contexts but are not universally standard. Always treat under specialist guidance. World Health Organization+1

1. Rifampin (rifampicin)
   Class: Rifamycin. Dose/Time (adults): Commonly 10 mg/kg once daily (max 600 mg) for 8 weeks when combined with clarithromycin (per WHO). Purpose: Core agent against M. ulcerans. Mechanism: Inhibits bacterial RNA polymerase. Side effects: Drug interactions (potent CYP inducer), hepatotoxicity, orange discoloration of fluids. Evidence source: FDA label (for TB and other uses) and WHO regimen for Buruli ulcer (off-label for BU in many countries). FDA Access Data+2FDA Access Data+2

2. Clarithromycin
   Class: Macrolide. Dose/Time (adults): 500 mg twice daily (or weight-based 7.5 mg/kg twice daily) with rifampin for 8 weeks. Purpose: Partner drug in all-oral regimen. Mechanism: Inhibits bacterial protein synthesis (50S ribosome). Side effects: GI upset, QT prolongation, CYP3A interactions. Evidence source: FDA label (approved for other infections), WHO and trials supporting CR8 regimen (off-label for BU). FDA Access Data+2FDA Access Data+2

3. Moxifloxacin
   Class: Fluoroquinolone. Dose/Time: 400 mg once daily (if used as alternative partner in selected cases). Purpose: Substitute where macrolides not tolerated. Mechanism: DNA gyrase/topoisomerase inhibition. Side effects: Tendon injury risk, QT prolongation, CNS effects. Evidence source: FDA label; limited BU data—use only if specialist advises. FDA Access Data+1

4. Levofloxacin
   Class: Fluoroquinolone. Dose/Time: Commonly 500–750 mg once daily (if chosen as alternate partner). Purpose/Mechanism: Similar to moxifloxacin. Side effects: Boxed warnings for tendinopathy, neuropathy, CNS effects. Evidence: FDA label; occasional BU use reported; specialist decision. FDA Access Data

5. Ciprofloxacin
   Class: Fluoroquinolone. Dose/Time: Often 500–750 mg twice daily in other skin infections; BU role is non-standard. Purpose: Alternative in combinations where appropriate. Mechanism/Side effects: Fluoroquinolone class. Evidence: FDA label (other indications), occasional BU reports; not first-line. FDA Access Data

6. Streptomycin (historical/selected cases)
   Class: Aminoglycoside (injection). Dose/Time: 15 mg/kg IM daily (max 1 g) historically with rifampin; now largely replaced by oral regimens. Purpose: Bactericidal; used when oral therapy not possible. Mechanism: 30S ribosomal inhibition. Side effects: Ototoxicity, nephrotoxicity, contraindicated in pregnancy. Evidence: FDA label; older WHO guidance. FDA Access Data+1

7. Amikacin (selected, specialist use)
   Class: Aminoglycoside (IV/IM). Dose/Time: Weight-based; reserved for severe disease or intolerance to other agents. Purpose: Broad antimycobacterial activity. Mechanism/Side effects: 30S inhibition; nephro/ototoxicity monitoring essential. Evidence: FDA documents (amikacin), expert consensus; off-label in BU. FDA Access Data+1

8. Azithromycin (selected combinations)
   Class: Macrolide. Dose/Time: Specialist-directed alternative macrolide if clarithromycin not tolerated. Mechanism/Side effects: 50S inhibition; QT prolongation interaction checks. Evidence: FDA label; limited BU data. FDA Access Data

9. Doxycycline (rare adjunct)
   Class: Tetracycline. Dose/Time: 100 mg twice daily as part of tailored regimens (non-standard). Purpose: Secondary spectrum if culture and sensitivity suggest benefit. Mechanism: 30S ribosome inhibition. Side effects: Photosensitivity, GI upset. Evidence: General antibiotic data; BU evidence limited—use only by specialists. Minerva Access

10. Cotrimoxazole (trimethoprim-sulfamethoxazole) (selected)
    Class: Folate pathway inhibitor combo. Use: Occasionally considered in tailored regimens if susceptibility supports; not first-line for BU. Cautions: Hypersensitivity, renal dosing. Evidence: In-vitro observations and expert reviews; clinical BU data limited. Minerva Access

11. Linezolid (rescue scenarios)
    Class: Oxazolidinone. Use: Salvage therapy under expert care only due to toxicity (myelosuppression, neuropathy). Evidence: General anti-mycobacterial experience; not standard for BU. PMC

12. Clofazimine (access-restricted in some countries)
    Class: Riminophenazine dye. Use: Sometimes explored for mycobacterial diseases; access and regulatory status vary; not FDA-approved for routine use. Cautions: Skin discoloration, GI effects. Evidence: Research/consensus papers; not standard BU therapy. Minerva Access

13. Reserved/individualized agents
    Depending on susceptibility testing, comorbidities, and specialist judgment, other agents may be considered on a case-by-case basis (eg, other macrolides or quinolones), but these are not routine for Buruli ulcer and may pose significant risks or lack evidence. Always prioritize rifampin + clarithromycin unless a specialist recommends otherwise. World Health Organization+1

Safety note: Many antibiotics above carry serious interaction and side-effect risks (eg, rifampin is a strong enzyme inducer; fluoroquinolones have boxed warnings). Always consult product labeling and a specialist. FDA Access Data+1

---

Dietary molecular supplements

1. Vitamin C
   Dose: 200–500 mg/day (upper limit 2,000 mg/day). Function: Cofactor for collagen synthesis; antioxidant. Mechanism: Hydroxylates proline/lysine in collagen, supports fibroblasts, and helps immune cells function. Note: Correct deficiency; megadoses can cause GI upset and kidney stones in predisposed people. Office of Dietary Supplements+1

2. Zinc
   Dose: 8–11 mg/day (dietary reference); short-term supplementation often 15–30 mg/day if deficient. Function: DNA/protein synthesis, immunity, epithelial repair. Mechanism: Supports keratinocyte migration and collagen cross-linking; deficiency delays healing. Caution: Excess zinc can cause copper deficiency and anemia. Office of Dietary Supplements+1

3. Arginine (L-arginine)
   Dose: 4–7 g/day in divided doses used in pressure-ulcer studies. Function: Substrate for nitric oxide; may aid immune responses and perfusion. Mechanism: Enhances T-cell function and collagen deposition; benefits shown in some wound-healing trials. Caution: Use under supervision in sepsis or renal/hepatic disease. PubMed+2Frontiers+2

4. Protein/Essential amino acids (eg, whey)
   Dose: Target total protein intake ~1.25–1.5 g/kg/day when malnourished. Function: Tissue repair, immune proteins. Mechanism: Supplies amino acids for collagen and granulation tissue; corrects protein-energy malnutrition common in chronic wounds. E-ACNM+1

5. Vitamin A
   Dose: Typically through diet; supplements only if deficient. Function: Epithelial differentiation and immune function. Mechanism: Supports keratinocyte proliferation and collagen remodeling. Caution: Avoid high doses in pregnancy; toxicity risk. PMC

6. Vitamin D
   Dose: Per deficiency status (often 800–2000 IU/day). Function: Immune modulation and muscle function. Mechanism: Affects innate/adaptive immunity; deficiency is common and may impair healing. ScienceDirect

7. Omega-3 fatty acids (EPA/DHA)
   Dose: 1–2 g/day EPA+DHA (food or supplement). Function: Modulate inflammation. Mechanism: Resolvins/protectins can temper excessive inflammation that delays healing. Caution: Bleeding risk with anticoagulants—ask your doctor. ScienceDirect

8. Probiotics (strain-specific)
   Dose: As labeled (eg, Lactobacillus/Bifidobacterium blends). Function: Gut support during antibiotics; possible immune benefits. Mechanism: Maintain microbiome balance, may reduce antibiotic-associated diarrhea and systemic inflammation. Evidence for wound healing is mixed—use as adjunct only. ScienceDirect

9. Copper (only if deficient)
   Dose: Usually via diet; supplements rarely needed. Function: Cofactor for lysyl oxidase in collagen cross-linking. Mechanism: Supports stable scar formation. Caution: Excess can be harmful; test deficiency first. PMC

10. Selenium (if deficient)
    Dose: 55 mcg/day typical; supplement only to correct low levels. Function: Antioxidant enzyme cofactor. Mechanism: Supports glutathione peroxidase activity and immune defenses. Caution: Narrow therapeutic window—avoid excess. PMC

---

Immunity-booster / regenerative / stem-cell drugs

There are no approved “stem-cell drugs” or immune-booster medicines specifically for Buruli ulcer. The proven path is antibiotics + wound care + nutrition + rehab. Below are six evidence-based medical supports sometimes involved, with honest limits:

1. Tetanus vaccination (as indicated) — protects against tetanus in open wounds; update per local schedule. Mechanism: Active immunization. Dose: Per national guidelines. WHO | Regional Office for Africa

2. Analgesics (eg, acetaminophen/NSAIDs as appropriate) — symptom control improves mobility and sleep; use the lowest effective dose and avoid NSAIDs if contraindicated. Mechanism: Central/peripheral analgesia; anti-inflammatory for NSAIDs. Medscape

3. Antihistamines (select cases) — help itch and sleep when dressings irritate skin. Mechanism: H1 blockade. Note: Symptomatic only. Medscape

4. Topical emollients after closure — support barrier repair of healed skin. Mechanism: Occlusion/hydration improves stratum corneum function. Dove Medical Press

5. Nutritional therapy (medical nutrition products) — protein/arginine-enriched formulas under dietitian guidance to correct malnutrition that impairs immunity and healing. Mechanism: Restores substrates for immune cells and collagen. E-ACNM+1

6. BCG (public-health context) — limited, non-specific protection against Buruli ulcer; not a treatment and not reliable prevention. Mechanism: Broad mycobacterial immune priming. World Health Organization

---

Surgeries (what they involve and why)

1. Conservative debridement – removal of dead tissue after antibiotics start; why: reduce necrosis and allow healthy granulation. SciSpace

2. Split-thickness skin graft – transplant of thin skin to cover clean granulating beds; why: speed closure of large ulcers and reduce contracture. Africa Health Organisation

3. Local flap coverage – rotate nearby healthy tissue to cover deeper defects; why: protect exposed tendons/bone. Africa Health Organisation

4. Contracture release – surgically free tight scars around joints; why: restore range of motion and function after healing. Africa Health Organisation

5. Abscess drainage/osteomyelitis procedures – drain pus or treat bone infection; why: control infection focus and save limb function. ScienceDirect

---

Preventions

Because transmission routes are not fully known, there’s no guaranteed primary prevention. Practical steps still help:

1. Seek care early for painless skin lumps/ulcers. World Health Organization

2. Use bed nets and reduce insect bites. PLOS

3. Keep wounds clean and covered. PLOS

4. Reduce stagnant water around homes if feasible. CDC

5. Wear protective clothing in high-risk areas. Health Victoria

6. Community education to cut diagnostic delays. CDC

7. Maintain good nutrition to support immunity. PMC

8. Keep vaccinations (eg, tetanus) current. WHO | Regional Office for Africa

9. Avoid self-surgery or harsh chemicals on ulcers. CDU Researchers

10. Support surveillance and prompt referral pathways. CDC

---

When to see a doctor (immediately)

See a clinician urgently if you have: a painless but expanding skin nodule/plaque/ulcer; swelling without fever; an ulcer that does not heal; signs of spreading infection (increasing redness, heat, bad odor); fever or severe pain; limited joint movement near the ulcer; any new ulcer after travel to or residence in an endemic area; or if you are pregnant, immunocompromised, or a child with a suspicious lesion. Early antibiotics prevent disability. Health Victoria+1

---

What to eat and what to avoid

1. Eat protein with every meal: eggs, fish, poultry, legumes, tofu. Protein fuels collagen and immune cells. E-ACNM

2. Add vitamin-C-rich foods: citrus, guava, berries, tomatoes, greens—support collagen. Office of Dietary Supplements

3. Include zinc sources: meat, seafood, beans, seeds, fortified grains—correcting deficiency improves healing. Office of Dietary Supplements

4. Stay hydrated: aim for ~30 mL/kg/day unless restricted. E-ACNM

5. Use healthy fats: fish, nuts, olive oil for anti-inflammatory support. ScienceDirect

6. Avoid excess alcohol: slows healing and worsens nutrition. ScienceDirect

7. Limit high-sugar ultra-processed foods: they displace protein/micronutrients. ScienceDirect

8. Correct deficiencies (vitamin D, iron, etc.) with clinician guidance. ScienceDirect

9. Small, frequent meals if appetite is poor—consider medical nutrition drinks as advised. E-ACNM

10. Don’t mega-dose supplements without testing—excess zinc or vitamin A can harm healing. Office of Dietary Supplements

---

Frequently Asked Questions

1) Is Buruli ulcer contagious between people?
Person-to-person spread is not proven; most evidence suggests environmental exposure. Health Victoria

2) What is the best antibiotic regimen?
Eight weeks of rifampin + clarithromycin is the current WHO-endorsed oral regimen for most patients. World Health Organization

3) Will I still need surgery?
Many patients heal without major surgery if treated early; some still need limited debridement or grafts depending on ulcer size and site. Medscape+1

4) How long until the wound closes?
Healing time varies with size and location. Proper antibiotics plus wound care shorten recovery compared with delayed treatment. The Lancet

5) Are there side effects from the medicines?
Yes. Rifampin interacts with many drugs and can affect the liver; macrolides and fluoroquinolones carry cardiac and tendon risks. Review all medicines with your clinician. FDA Access Data+1

6) Can children and pregnant people be treated?
Yes—regimens are adjusted by weight and safety. Specialist care is essential to balance benefits/risks and select safe agents. WHO | Regional Office for Africa

7) Does BCG vaccine prevent Buruli ulcer?
It offers limited protection and is not a reliable preventive measure for this disease. World Health Organization

8) What dressings are best?
Moisture-retentive, atraumatic dressings chosen by a wound-care professional; change frequency depends on exudate and infection risk. CDU Researchers

9) Should I use antiseptics or herbal pastes on the ulcer?
Avoid harsh chemicals or unproven pastes; they can damage tissue and delay healing. Use clinician-advised cleansing only. CDU Researchers

10) Do I need physical therapy?
Yes if the ulcer is near a joint or large. Early, gentle movement prevents stiffness and disability. Africa Health Organisation

11) How do I lower my chance of getting it again?
Seek care early for new lesions, reduce insect bites, keep minor wounds clean, and support community surveillance. PLOS+1

12) Can poor diet slow healing?
Yes. Protein-energy malnutrition and lack of key micronutrients (vitamin C, zinc) impair collagen and immune functions. PMC

13) Are probiotics useful while on antibiotics?
They may help with antibiotic-related gut effects; wound-healing benefits are uncertain. Discuss strains and timing with your clinician. ScienceDirect

14) Why did my urine turn orange on treatment?
Rifampin commonly turns urine, sweat, and tears orange—this is expected. Report any jaundice or severe symptoms immediately. FDA Access Data

15) Where can clinicians find full guidance?
WHO manual “Treatment of Mycobacterium ulcerans disease (Buruli ulcer)” and recent consensus papers outline diagnosis, antibiotics, wound care, and rehab. WHO | Regional Office for Africa+2World Health Organization+2

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 06, 2025.

PDF Documents For This Disease Condition References